DOCSLIB.ORG

2020 ICD-10 List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 ICD-10 List 2020 ICD-10 List Acanthosis Nigricans L83 Hyperhidrosis, Axillae L74.510 SK, Asymptomatic L82.1 Acne L70.0 Hyperhidrosis, Palms L74.512 SK, Inflammed L82.0 Actinic Keratosis L57.0 Hyperkeratosis L85.8 Skin Tags L91.8 Alopecia, Areata L63.8 Hyperpigmentation L81.8 Stria Atrophica L90.6 Alopecia, Androgenic L64.8 Hyopigmentation L81.6 Sunburn L55.9 Angioma(s) D18.01 Ichthyosis Q80.8 Telangiectasia I78.8 Angular Chilitis K13.0 Impetigo, non bullous L01.01 Telogen Effluvium L65.0 Bullous Pemphigoid L12.0 Infection NOS, Skin L08.9 TINEA Café Au Lait L81.3 Intertrigo L30.4 Capitis B35.0 Callus/Corn L84 Kaposi's Sarcoma C46.0 Corporis B35.4 Candidiasis, Skin/Nail B37.2 Keloid L91.0 Cruris B35.6 CARP L83 Keratoderma, Acquired L85.1 Manuum B35.2 CNH - right ear H61.021 Keratosis Pilaris Q82.8 Pedis B35.3 CNH - left ear H61.022 Lentigo L81.4 Unguium B35.1 Condyloma, Acuminata A63.0 Lichen Planus L43.8 Versicolor B36.0 Cyst Lichen Sclerosus L90.0 Urticaria L50.1 Epidermal L72.0 Lichen Simplex Chronicus L28.0 Varicella B01.9 Mucoid/Myxoid/Ganglion M67.40 Lipodermatosclerosis I83.10 Vasculitis L95.8 Pilar L72.11 Lupus, Discoid L93.0 Venous Insufficiency I87.2 Sebaceous L72.3 Lupus, Systemic M32.10 Venous Lake L98.8 Dariers Disease Q82.8 Lymphedema I89.0 Verruca, Anogenital A63.0 Delusions of Parasitosis F45.8 Melasma L81.1 Verruca, Plantar B07.0 Dermatitis Milia L72.0 Verruca, Vulgaris B07.8 Actinic L57.8 Molluscum B08.1 Viral Exanthem B09 Atopic L20.89 Morphea L94.0 Vitiligo L80 Diaper L22 Mucocele K11.6 Xanthoma E78.2 Eczematous L30.8 Nail Dystrophy L60.3 Xerosis L85.3 Hand L30.8 Nail Disorder NOS L60.9 Factitial L98.1 Nail, Ingrown L60.0 Herpertiformis L13.0 Neurofibromatosis NOS Q85.00 History of Skin Cancer Lichenoid L28.0 Neurotic Excoriations L91.8 Personal Hx of Skin Cancer Z85.828 Neurodermatitis L30.8 Notalgia Paresthetica R20.2 Personal Hx of SCC-IS Z86.007 Perioral L71.0 Onycholysis L60.1 Personal Hx of MM Z85.820 Rhus L23.7 Onychomycisis B35.1 Personal Hx of MM-IS Z86.006 Sebhorrheic L21.8 Paronychia, Right Finger L03.011 Family Hx of MM Z80.8 Stasis I87.2 Paronychia, Left Finger L03.012 Dermatographia L50.3 Perleche K13.0 Discoid Lupus L93.0 Petechiae R23.3 Long Term use of Drug Rash, generalized L27.0 PIH L81.0 Antibiotics Z79.2 Drug Rash, localized L27.1 Pityriasis alba L30.5 Systemic Steroids Z79.52 Dyschromia L81.9 Pityriasis Rosea L42 Other Drug Therapy Z79.899 Ecchymosis R23.3 Pityriasis rubra pilaris L44.0 Eczema Poikiloderma of Civeatte L57.3 Dyshidrotic L30.1 Port Wine Stain Q82.5 Miscellaneous NOS L30.9 Post-Herpatic Neuralgia B02.29 Cosmetic Z41.9 Nummular L30.0 Prurigo Nodularis L28.1 Dressing Change Z48.01 Xerotic L85.3 Pruritus L29.8 Post Surgical Care Z48.817 Edema R60.0 Pseudofolliculitis barbae L73.1 Suture Removal Z48.02 Erythema Nodosum L52 Psoriasis, plaque L40.0 Screening for Malignancy Z12.83 Erythrasma L08.1 Psoraisis, palmar plantar L40.3 Flushing R23.2 Psorasis, nails L40.8 Foreign Body Granuloma L92.3 Psoriatic Arthritis L40.59 Neoplasm of Freckles L81.2 Purpura D69.2 Uncertain Behavior D48.5 Gianotti-Crosti L44.4 Pyoderma Gangrenosum L88 Unspecified Behavior D49.2 Glossitis K14.0 Pyoderma L08.0 Granuloma Annulare L92.0 Pyogenic Granuloma L98.0 Grovers Disease L11.1 Rash, Unspecified R21 Secondary Diagnoses Hematoma/Bleeding Postop L76.21 Rosacea L71.8 Bleeding R58 Herpes Simplex B00.1 Rhytides L98.8 Inflamed L53.8 Herpes Zoster B02.9 Scabies B86 Itching L29.8 Hidradenitis Suppurativa L73.2 Scar L90.5 Painful R52 Hirsutism L68.0 Sebaceous Hyperplasia L73.8 Trauma, Risk of/Subject to R20.8 2020 Site Specific ICD-10 Codes Basal Cell Carcinoma Squamous Cell Carcinoma Squamous cell Carcinoma In-Situ Lip C44.01 Lip C44.02 Lip D04.0 R upper eyelid C44.1121 R upper eyelid C44.1221 R upper eyelid D04.111 R lower eyelid C44.1122 R lower eyelid C44.1222 R lower eyelid D04.112 L upper eyelid C44.1191 L upper eyelid C44.1291 L upper eyelid D04.121 L lower eyelid C44.1192 L lower eyelid C44.1292 L lower eyelid D04.122 R ear C44.212 R ear C44.222 R ear D04.21 L ear C44.219 L ear C44.229 L ear D04.22 Face C44.319 Face C44.329 Face D04.39 Scalp and Neck C44.41 Scalp and Neck C44.42 Scalp and Neck D04.4 Trunk C44.519 Trunk C44.529 Trunk D04.5 R upper extremity C44.612 R upper extremity C44.622 R upper extremity D04.61 L upper extremity C44.619 L upper extremity C44.629 L upper extremity D04.62 R lower extremity C44.712 R lower extremity C44.722 R lower extremity D04.71 L lower extremity C44.719 L lower extremity C44.729 L lower extremity D04.72 Malignant Melanoma Melanoma In-Situ Other Unspec. Malignant Neoplasm Lip C43.0 Lip D03.0 Lip C44.09 R upper eyelid C43.111 R upper eyelid D03.111 R upper eyelid C44.1021 R lower eyelid C43.112 R lower eyelid D03.112 R lower eyelid C44.1022 L upper eyelid C43.121 L upper eyelid D03.121 L upper eyelid C44.1091 L lower eyelid C43.122 L lower eyelid D03.122 L lower eyelid C44.1092 R ear C43.21 R ear D03.21 R ear C44.202 L ear C43.22 L ear D03.22 L ear C44.209 Face C43.39 Face D03.39 Face C44.309 Scalp and Neck C43.4 Scalp and Neck D03.4 Scalp and Neck C44.4 Trunk C43.59 Trunk D03.59 Trunk C44.509 R upper extremity C43.61 R upper extremity D03.61 R upper extremity C44.602 L upper extremity C43.62 L upper extremity D03.62 L upper extremity C44.609 R lower extremity C43.71 R lower extremity D03.71 R lower extremity C44.702 L lower extremity C43.72 L lower extremity D03.72 L lower extremity C44.709 Benign Neoplasm (DF, FP) Nevus, Benign/Melanocytic Lipoma Lip D23.0 Lip D22.0 Lip n/a R upper eyelid D23.111 R upper eyelid D22.111 R upper eyelid n/a R lower eyelid D23.112 R lower eyelid D22.112 R lower eyelid n/a L upper eyelid D23.121 L upper eyelid D22.121 L upper eyelid n/a L lower eyelid D23.122 L lower eyelid D22.122 L lower eyelid n/a R ear D23.21 R ear D22.21 R ear n/a L ear D23.22 L ear D22.22 L ear n/a Face D23.39 Face D22.39 Face D17.0 Scalp and Neck D23.4 Scalp and Neck D22.4 Scalp and Neck D17.0 Trunk D23.5 Trunk D22.5 Trunk D17.1 R upper extremity D23.61 R upper extremity D22.61 R upper extremity D17.21 L upper extremity D23.62 L upper extremity D22.62 L upper extremity D17.22 R lower extremity D23.71 R lower extremity D22.71 R lower extremity D17.23 L lower extremity D23.72 L lower extremity D22.72 L lower extremity D17.24 Abcess Cellulitis Furuncle Neck L02.11 Lip K13.0 Lip n/a R upper eyelid H00.031 R upper eyelid H00.011 R upper eyelid H00.031 R lower eyelid H00.032 R lower eyelid H00.012 R lower eyelid H00.032 L upper eyelid H00.034 L upper eyelid H00.014 L upper eyelid H00.034 L lower eyelid H00.035 L lower eyelid H00.015 L lower eyelid H00.035 R ear H60.01 R ear H60.11 R ear H60.01 L ear H60.02 L ear H60.12 L ear H60.02 Face L02.01 Face L03.211 Face L02.02 Head and Scalp L02.811 Neck L03.221 Scalp and Neck L02.12 Abdomen L02.211 Trunk L03.311 Trunk L02.229 Back L02.212 R upper extremity L03.113 R upper extremity L02.423 Chest L02.213 L upper extremity L03.114 L upper extremity L02.424 R upper extremity L02.413 R lower extremity L03.115 R lower extremity L02.425 L upper extremity L02.414 L lower extremity L03.116 L lower extremity L02.426 R lower extremity L02.415 Scalp L03.811 L lower extremity L02.416 .
Load more

Recommended publications
  • Training Available: in 2012, Lorenzo Kunze, M.E
    2013 Derma-Lo - offers the 2013 Thermo-Lo - offers the reduction of: sun/age spot, milia, reduction of: sun/age spot, milia, telangiectasia / epidermal spider telangiectasia / epidermal spider veins, cherry hemangiomas, veins, cherry hemangiomas and Thermolysis (AC) and Electrolysis Thermolysis (AC) hair removal. (DC) hair removal. Also: active acne, acne scarring, sebaceous hyperplasia, and skin tags. Training Available: In 2012, Lorenzo Kunze, M.E. Includes: Hydro-Lo - treatment IN DENVER ONCE A MONTH developed Chromos, Inc. - which of fine lines and wrinkles, TRAINING AVAILABLE AT in Greek, can be interpreted as enlarged pore reduction, boosts YOUR LOCATION ASK ABOUT “color” or “light” – in essence, the penetration of product into COST without light we have no color. the skin and tightens loose skin. “Dedicated to Excellence” Also: select your choice of (1 of Continuing to provide a professional & positive attitude in the medical 2) LED’s – both are non invasive and aesthetic field. hand-held light probes: BLUE for CHROMOS, Inc. the treatment of acne or Lorenzo Kunze, M.E. Chromos strives to be a guiding INFRARED to increase collagen [email protected] “light” that assists medical and and elastin, Rosacea, increased www.DermaLo.com aesthetic professionals in finding healing properties, minor muscle www.Thermo-Lo.com and pursuing proper education and moderate joint pain. 888-499-8991 / 303-994-7236 and accurate knowledge. Lorenzo Kunze, M.E. Lorenzo is a true visionary - 40 years in the medical and aesthetic field Medical Electrologist / medical educator 1st non-medical professional to provide electrolysis treatments in an OR Treated over 20,000 patients - last 16 years 1st in the U.S.
    [Show full text]
  • Dermatology DDX Deck, 2Nd Edition 65
    63. Herpes simplex (cold sores, fever blisters) PREMALIGNANT AND MALIGNANT NON- 64. Varicella (chicken pox) MELANOMA SKIN TUMORS Dermatology DDX Deck, 2nd Edition 65. Herpes zoster (shingles) 126. Basal cell carcinoma 66. Hand, foot, and mouth disease 127. Actinic keratosis TOPICAL THERAPY 128. Squamous cell carcinoma 1. Basic principles of treatment FUNGAL INFECTIONS 129. Bowen disease 2. Topical corticosteroids 67. Candidiasis (moniliasis) 130. Leukoplakia 68. Candidal balanitis 131. Cutaneous T-cell lymphoma ECZEMA 69. Candidiasis (diaper dermatitis) 132. Paget disease of the breast 3. Acute eczematous inflammation 70. Candidiasis of large skin folds (candidal 133. Extramammary Paget disease 4. Rhus dermatitis (poison ivy, poison oak, intertrigo) 134. Cutaneous metastasis poison sumac) 71. Tinea versicolor 5. Subacute eczematous inflammation 72. Tinea of the nails NEVI AND MALIGNANT MELANOMA 6. Chronic eczematous inflammation 73. Angular cheilitis 135. Nevi, melanocytic nevi, moles 7. Lichen simplex chronicus 74. Cutaneous fungal infections (tinea) 136. Atypical mole syndrome (dysplastic nevus 8. Hand eczema 75. Tinea of the foot syndrome) 9. Asteatotic eczema 76. Tinea of the groin 137. Malignant melanoma, lentigo maligna 10. Chapped, fissured feet 77. Tinea of the body 138. Melanoma mimics 11. Allergic contact dermatitis 78. Tinea of the hand 139. Congenital melanocytic nevi 12. Irritant contact dermatitis 79. Tinea incognito 13. Fingertip eczema 80. Tinea of the scalp VASCULAR TUMORS AND MALFORMATIONS 14. Keratolysis exfoliativa 81. Tinea of the beard 140. Hemangiomas of infancy 15. Nummular eczema 141. Vascular malformations 16. Pompholyx EXANTHEMS AND DRUG REACTIONS 142. Cherry angioma 17. Prurigo nodularis 82. Non-specific viral rash 143. Angiokeratoma 18. Stasis dermatitis 83.
    [Show full text]
  • Rosacea: an Update
    REVIEW JONELLE K. MCDONNELL, MD KENNETH J. TOMECKI, MD Department of Dermatology, Cleveland Clinic Department of Dermatology, Cleveland Clinic Rosacea: An update • ABSTRACT | >1 OSACEA is a chronic and recurrent LAM inflammatory skin disease characterized Rosacea is a common inflammatory skin disease affecting by erythema, papules, pustules, telangiectasia, the central face of adults. Its etiology is unknown. Early and occasionally sebaceous hyperplasia, which diagnosis and appropriate treatment, usually with topical or primarily affects the central face. The disease systemic antibiotics or both, minimizes symptoms and helps evolves in stages and affects middle-aged to prevent complications. adults. Early diagnosis and thoughtful manage- ment help to control the disease and to mini- • KEY POINTS mize the patient's discomfort and emotional distress. Historically, rosacea has been a mis- Rosacea has a spectrum of cutaneous clinical findings: understood disorder, often attributed to alco- facial erythema, papules, pustules, telangiectasia, and holism and acne.1 rhinophyma. • INCIDENCE Common triggers are sunlight, stress, exposure to extreme Rosacea is a common and chronic disease that heat or cold, alcohol, hot beverages, and spicy foods. affects approximately 13 million Americans, or about 1 in 20 people. Because rosacea fre- Rosacea can resemble other diseases, including acne, quently affects people of northern European seborrheic dermatitis, systemic lupus erythematosus, and heritage, it is often called the "curse of the sarcoidosis. Celts."2 In contrast, it is rarely seen in dark- skinned individuals.3 In most patients, the Ocular involvement occurs in more than 50% of patients onset occurs between the ages of 30 and 50. with rosacea. The early stages affect women more often than men at a ratio of 3 to 1, but men more often Oral tetracycline and topical metronidazole are the develop disfiguring rhinophyma.
    [Show full text]
  • A Case of Steatocystoma Simplex Involving the Scalp
    230 A Case of Steatocystoma Simplex Involving the Scalp Dong Nyeok Hyun, M.D., Jong Hoon Won, M.D., Joon Soo Park, M.D., Hyun Chung, M.D. Department of Dermatology, School of Medicine, Catholic University of Daegu, Daegu, Korea Steatocystoma is a benign adnexal tumor originating from the pilosebaceous duct junction which can be classified into two groups (steatocystoma simplex and steatocystoma multiplex). Steatocystoma simplex, which presents as a solitary lesion, is very rare. Steatocystoma simplex occurs most commonly on the face and the case reported herein involving the scalp is extremely rare. A 49-year-old man presented for evaluation and treatment of a solitary papule on the right parietal scalp which had persisted for a period of 1 year. The histopathologic examination revealed a thin-walled cyst consisting of stratified squamous epithelium with hyaline cuticle that lacked a stratum granulosum. Based on clinical and histologic findings, we diagnosed this case as steatocystoma simplex of the scalp and report this rare case. (Ann Dermatol (Seoul) 20(4) 230∼232, 2008) Key Words: Scalp, Steatocystoma simplex INTRODUCTION CASE REPORT Steatocystoma simplex, first described as a dis- A 49-year-old man presented to our outpatient tinct entity by Brownstein1 in 1982, is an extremely clinic with an asymptomatic papule on the right rare benign adnexal tumor. The individual lesion of parietal scalp which had been present for about 1 steatocystoma simplex is usually identical with that year. The lesion had slowly enlarged a few months of steatocystoma multiplex, both clinically and ago. The physical examination revealed a skin- histologically, but is characterized by solitary, non- colored, deep-seated, soft cystic mass on his right heritable growth in adulthood1.
    [Show full text]
  • Pathogenesis of Rosacea Anetta E
    REVIEW Pathogenesis of Rosacea Anetta E. Reszko, MD, PhD; Richard D. Granstein, MD Rosacea is a chronic, common skin disorder whose pathogenesis is incompletely understood. An inter- play of multiple factors, including genetic predisposition and environmental, neurogenic, and microbial factors, may be involved in the disease process. Rosacea subtypes, identified in the recently published standard classification system by the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea, may in fact represent different disease processes, and identifying subtypes may allow investigators to pursue more precisely focused studies. New developments in molecular biology and genetics hold promise for elucidating the interplay of the multiple factors involved in the pathogen- esis of rosacea, as well as providing the bases for potential new therapies. osacea is a common, chronic skin disorder and secondary features needed for the clinical diagnosis primarily affecting the central and con- of rosacea. Primary features include flushing (transient vex areas of COSthe face. The nose, cheeks, DERM erythema), persistent erythema, papules and pustules, chin, forehead, and glabella are the most and telangiectasias. Secondary features include burn- frequently affected sites. Less commonly ing and stinging, skin dryness, plaque formation, dry affectedR sites include the infraorbital, submental, and ret- appearance, edema, ocular symptoms, extrafacial mani- roauricular areas, the V-shaped area of the chest, and the festations, and phymatous changes. One or more of the neck, the back, and theDo scalp. Notprimary Copy features is needed for diagnosis.1 The disease has a variety of clinical manifestations, Several authors have theorized that rosacea progresses including flushing, persistent erythema, telangiecta- from one stage to another.2-4 However, recent data, sias, papules, pustules, and tissue and sebaceous gland including data on therapeutic modalities of various sub- hyperplasia.
    [Show full text]
  • Cancer Immunoprevention: a Case Report Raising the Possibility of “Immuno-Interception” Jessica G
    CANCER PREVENTION RESEARCH | RESEARCH BRIEF Cancer Immunoprevention: A Case Report Raising the Possibility of “Immuno-interception” Jessica G. Mancuso1, William D. Foulkes1,2,3, and Michael N. Pollak1,2 ABSTRACT ◥ Immune checkpoint blockade therapy provides substan- or neoplastic lesions over a period of 19 years (mean tial benefits for subsets of patients with advanced cancer, 7.5 neoplasms/year, range 2–26) prior to receiving but its utility for cancer prevention is unknown. Lynch pembrolizumab immunotherapy as part of multi- syndrome (MIM 120435) is characterized by defective modality treatment for invasive bladder cancer. He not DNA mismatch repair and predisposition to multiple only had a complete response of the bladder cancer, but cancers. A variant of Lynch syndrome, Muir–Torre also was noted to have an absence of new cancers during a syndrome (MIM 158320), is characterized by frequent 22-month follow-up period. This case adds to the rationale gastrointestinal tumors and hyperplastic or neoplastic skin for exploring the utility of immune checkpoint blockade tumors. We report the case of a man with Muir–Torre forcancerprevention,particularlyforpatientswithDNA syndrome who had 136 cutaneous or visceral hyperplastic repair deficits. Introduction There is an obvious clinical need to reduce cancer incidence in patients with DNA repair deficits, and prophylactic surgery The clinically demonstrated utility of antiviral vaccines to is commonly employed. Clinical trials designed to evaluate reduce risk of virally initiated cancers represents a major strategies to reduce cancer incidence are challenging: in popu- success in cancer immunoprevention. There is interest in the lations where baseline risk is low, a large number of subjects and possibility that immunoprevention may also be useful where long follow-up periods are required.
    [Show full text]
  • Price Sheet 01-01-21
    SERVICES & PRICING DERM CASH PRICES – FOR COSMETIC PROCEDURES Sebaceous Hyperplasia (Any #) . $150.00 Milia (Any #) . $100.00 Seborrheic Keratoses (Full Back Greater than 40) . $500.00 Seborrheic Keratoses (Half Back) . $250.00 Seborrheic Keratosis (Face) . $200.00 Lentigo (1-5 with TCA) . $150.00 Cherry Angiomas (Per Region) . $150.00 Benign Nevi (Per Spot) . $150.00 Skin Tags (1-15) . $100.00 Skin Tags (16 -25) . $150.00 Skin Tags (26 or more) . $250.00 AEROLASE CONDITION QTY FREQUENCY COST PER QTY. LENTIGO (1) 3 – 4 EVERY 3 – 4 WEEKS $50.00 LENTIGO (2-5) 3 – 4 EVERY 3 – 4 WEEKS $150.00 LENTIGOS (FULL FACE) 3 – 4 EVERY 3 – 4 WEEKS $250.00 FRECKLING/PIH 3 – 4 EVERY 3 – 4 WEEKS $275.00 MELASMA 4+ EVERY 3 – 4 WEEKS $250.00 ANGIOMA (1) 2 – 3 EVERY 3 – 4 WEEKS $50.00 ANGIOMAS (2-5) 2 – 3 EVERY 3 – 4 WEEKS $150.00 ANGIOMAS (FULL FACE) 2 – 3 EVERY 3 – 4 WEEKS $250.00 TELANGECTASIAS (FACE) 2 – 3 EVERY 3 – 4 WEEKS $250.00 SPIDER VEINS (LEGS) 3 – 4 EVERY 3 – 4 WEEKS $500.00 POIKILODERMA 3 – 4 EVERY 3 – 4 WEEKS $300.00-400.00 SCARS (1-5) 4 EVERY 3 – 4 WEEKS $150.00 STRETCH MARKS 4 EVERY 3 – 4 WEEKS $250.00 FACIAL REJUVENATION 4 EVERY 3 – 4 WEEKS $400.00 PSEUDOFOLLICULITIS BARBAE 3 – 4 EVERY 2 – 3 WEEKS $150.00 AMOUNT BILLED ACNE AND/OR ROSACEA *INSURANCE 4+ EVERY 2 WEEKS TO INSURANCE $180.00 IF PAID IN FULL ACNE AND/OR ROSACEA * CASH 4+ EVERY 1 –2 WEEKS AT TIME OF SERVICE $126.00 WARTS *INSURANCE 2+ EVERY 2 – 3 WEEKS --- WARTS * CASH 2+ EVERY 2 – 3 WEEKS $100.00 PSORIASIS $ (SMALL AREA) 6+ 1 WEEK $100.00 PSORIASIS - INSURANCE (PA REQ.) 6+ EVERY 2 WEEKS --- WOUND HEALING 3 – 6 1 – 2 TIMES A WEEK $150.00 TOENAIL FUNGUS (PER TOE) 1 – 4 EVERY 4 WEEKS $100.00 *Cash price for patients without insurance.
    [Show full text]
  • The Treatment of Giant Rhinophyma - Case Report (1) (2) D
    Current Health Sciences Journal Vol. 38, No. 2, 2012 April June Case Report The treatment of giant rhinophyma - Case Report (1) (2) D. POPA , GEORGETA OSMAN , H. (1) (3) (1) PARVANESCU ,RALUCA CIUREA , M. CIUREA (1) Department of Plastic and Reconstructive Surgery, University of Medicine and Pharmacy of Craiova; (2) Departament of E.N.T., Emergency University Hospital, Craiova, (3) Department of Pathology, University of Medicine and Pharmacy of Craiova ABSTRACT The aim of the article is to present an update on the pathophysiology, clinical features and treatment of rhinophyma. A 56 years old patient, living in urban area, presented with a giant rhinophyma which caused him not only upper airways obstruction and difficulty in eating, but also aesthetic and psycho-social disadvantages.The treatment of the patient was a surgical intervention consisting in removal of the nasal tumor and split-thickness skin grafting of the defect. The aesthetic result after surgical intervention was very good, there were no postoperative complications or recurrences.Rhinophyma represents the most advanced form of acne rosacea. The diagnosis is easy to establish based on the clinical features of the disease. In advanced forms of rhinophyma, when the tumor is giant, the main method of treatment is surgery. KEY WORDS rhinophyma , sebaceous hyperplasia, nasal tumor Introduction Rhinophyma, exuberant hypertrophic acne, with tumoral aspect of the skin of nasal pyramid is characterized by large, bulbous, erythematous appearance of the nose. It can also cause upper airways obstruction and difficulty in eating. The word rhinophyma is derived from the Greek word “rhis” meaning nose and “phyma” meaning growth .This disease mainly occurs in men after 50 years.
    [Show full text]
  • Treatment of Aged Skin with Oral 13-Cis-Retinoic Acid
    Europaisches Patentamt European Patent Office © Publication number: 0 357 646 B1 Office europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 22.03.95 © Int. CI.6: A61 K 31/07, A61 K 31/20 © Application number: 88903704.0 @ Date of filing: 05.04.88 © International application number: PCT/US88/01103 © International publication number: WO 88/07857 (20.10.88 88/23) The file contains technical information submitted after the application was filed and not included in this specification © TREATMENT OF AGED SKIN WITH ORAL 13-CIS-RETINOIC ACID. ® Priority: 06.04.87 US 35544 © Proprietor: DALTEX MEDICAL SCIENCES, INC. 50 Kulick Road @ Date of publication of application: Second Floor 14.03.90 Bulletin 90/11 Fairfield, NJ 07006 (US) © Publication of the grant of the patent: @ Inventor: PLEWIG, Gerd 22.03.95 Bulletin 95/12 Cecilienallee 38 D-4000 Dusseldorf 30 (DE) © Designated Contracting States: Inventor: KLIGMAN, Albert, M. AT BE CH DE FR GB IT LI LU NL SE 637 Pine Street Philadelphia, PA 19106 (US) © References cited: GB-A- 1 335 867 Representative: Koepsell, Helmut, Dipl. Ing. Retinoids, ED.; C.E. ORFANOS et al., pub- Mittelstrasse 7 lished 29 July 1981, pp. 219-223, 232-235, see D-50672 Koln (DE) entire document 00 CO CO m Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art.
    [Show full text]
  • Photodynamic Therapy and Skin Appendage Disorders: a Review
    Review Article Skin Appendage Disord 2016;2:166–176 Received: September 28, 2016 DOI: 10.1159/000453273 Accepted: November 7, 2016 Published online: December 8, 2016 Photodynamic Therapy and Skin Appendage Disorders: A Review Matteo Megna Gabriella Fabbrocini Claudio Marasca Giuseppe Monfrecola Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples , Italy Key Words Introduction Photodynamic therapy · Hidradenitis suppurativa · Acne · Sebaceous hyperplasia · Onychomycosis Photodynamic therapy (PDT) is a noninvasive treat- ment that utilizes light treatment along with an applica- tion of a photosensitizing agent in the presence of mo- Abstract lecular oxygen [1–3] . The scientific basis of PDT has Photodynamic therapy (PDT) is a noninvasive treatment that been recognized since 1900; Oscar Raab and Herman utilizes light treatment along with application of a photosen- von Tappeiner were first to report the concept of cell sitizing agent. In dermatology, PDT is commonly used and death being induced by the interaction of light and chem- approved for the treatment of oncological conditions such icals [4–5] . Shortly afterwards, von Tappeiner and Je- as actinic keratosis, Bowen disease and superficial basal cell sionek [6] performed the first medical application in der- carcinoma. In the last 2 decades however, PDT has also been matology, using a combination of topical eosin and white used for the treatment of several nonneoplastic dermato- light to treat skin tumors. Nevertheless, numerous
    [Show full text]
  • A 5 Year Histopathological Study of Skin Adnexal Tumors at a Tertiary Care Hospital
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 14, Issue 4 Ver. VII (Apr. 2015), PP 01-05 www.iosrjournals.org A 5 Year Histopathological Study of Skin Adnexal Tumors at a Tertiary Care Hospital Dr.Vani.D1, Dr.Ashwini.N.S2, Dr.Sandhya.M3, Dr.T.R.Dayananda4, Dr.Bharathi.M5 1,2,3,5, Department of Pathology, Mysore Medical College & Research Institute, Mysore, India 4, Department of Dermatology, BGS Apollo Hospital, Mysore, India Abstract: Introduction: Skin adnexal neoplasms are uncommon and are daunting diagnostic problems in view of the wide spectrum of lesions and their variants. Benign adnexal neoplasms are more common than malignant lesions. Aim: To study histopathology of skin adnexal neoplasms and to correlate with the clinical profile. Methodology: 51cases with a diagnosis of skin adnexal neoplasm over a 5 year period reported in the Department of Pathology, Mysore Medical College & Research Institute were included in the study. Histopathological examination was done on Haematoxylin& Eosin stained slides and corroborated with special stains wherever required. Results: Skin adnexal tumors were most common in the age group of 40 to 49 years (21.56%, 11/51). Male to female ratio was 1:1.68. The head and neck region was the most common site affected (64.70%, 33/51) with 39.21% (20/51) caseslocated on the face. 74.50% (38/51) cases were benign and 25.49% (13/51) cases were malignant. The sweat gland tumors formed the largest group involving 43.13% (22/51) cases followed by the hair follicle tumors 37.25% (19/51) followed by sebaceous gland tumors 19.60% (10/51).
    [Show full text]
  • Buffalo Medical Group, P.C. Robert E
    Buffalo Medical Group, P.C. Robert E. Kalb, M.D. Phone: (716) 630-1102 Fax: (716) 633-6507 Department of Dermatology 325 Essjay Road Williamsville, New York 14221 2 FOOT- 1 HAND SYNDROME 2 foot - 1 hand syndrome is a superficial infection of the skin caused by the common athlete's foot fungus. It is quite common for people to have a minor amount of an athlete's foot condition. This would appear as slight scaling and/or itching between the toes. In addition, patients may have thickened toenails as part of the athlete's foot condition. Again the problem on the feet is very common and often patients are not even aware of it. In some patients, however, the athlete's foot fungus can spread to another area of the body. For some strange and unknown reason, it seems to affect only one hand. That is why the condition is called 2 foot - 1 hand syndrome. It is not clear why the problem develops in only one hand or why the right or left is involved in some patients. Fortunately there is very effective treatment to control this minor skin problem. If the problem with the superficial fungus infection is confined to the skin, then a short course of treatment with an oral antibiotic is all that is required. This antibiotic is very safe and normally clears the skin up fairly rapidly. It is often used with a topical cream to speed the healing process. If, however, the fingernails of the affected hand are also involved then a more prolonged course of the antibiotic will be necessary.
    [Show full text]